A Randomized Placebo-Controlled Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC); R2810-ONC-1788

Brief description of study

The main purpose of this study is to determine if the study drug, Cemiplimab, will prevent cutaneous squamous cell cancer from returning after surgery and radiation. The information from this study may also be used to better understand the following additional research questions: • To see if cemiplimab may help you live for longer • To understand how study participation affects how you feel. This is sometimes called “quality of life.” • Side effects that you may experience during the study

Clinical Study Identifier: s18-01608
ClinicalTrials.gov Identifier: NCT03969004
Principal Investigator: Janice Mehnert.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.